“Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years”, J of Skin, vol. 7, no. 2, p. s150, Mar. 2023, doi: 10.25251/skin.7.supp.150.